metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Serum determination of MMP-2 and MMP-9 in chronic liver disease according to alc...
Journal Information
Vol. 27. Issue S3.
Abstracts from XVII Mexican Congress of Hepatology
(December 2022)
Share
Share
Download PDF
More article options
Vol. 27. Issue S3.
Abstracts from XVII Mexican Congress of Hepatology
(December 2022)
Open Access
Serum determination of MMP-2 and MMP-9 in chronic liver disease according to alcohol consumption, non-alcoholic fatty liver disease and hepatitis C
Visits
565
M Lemus-Peña1, D Montes de Oca-Ángeles1, M Hernandez-Santillan1, A Hernandez-Barragan1, D Santana-Vargas2, M Martinez-Castillo1, Z Medina-Avila1, A Torre-Delgadillo2, JL Pérez-Hernández2, F Higuera-De la Tijera2, P Cordero-Pérez3, L Muñoz-Espinosa3, D Kershenobich4, G Gutiérrez-Reyes1
1 Liver, Pancreas and Motility Laboratory. Unit of Research in Experimental Medicine. School of Medicine. UNAM. Mexico City. Mexico
2 Department of Gastroenterology. General Hospital of México “Dr. Eduardo Liceaga.” México City. México
3 Universitary Hospital “Dr. José Eluterio González”. School of Medicine. UANL. Nuevo Leon. Mexico
4 National Institute of Medical Sciences and Nutrition “Salvador Zubirán.” México City. Mexico
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 27. Issue S3

Abstracts from XVII Mexican Congress of Hepatology

More info
Introduction and Objective

This study aimed to evaluate serum concentration of MMP-2 and -9 in different etiologies of liver disease also according to fibrosis stages.

Materials and methods

Cross-sectional multicentric study, including subjects with no alcoholic fatty liver disease (NAFLD), chronic Hepatitis C (CHC), alcohol cirrhosis (CiOH) and alcoholism (OH), groups with alcohol drinking habits were classified according to OMS criteria, with clinical and biochemical evidence of alcoholic liver disease (ALD). Transitional elastography (Fibroscan) was performed in NAFLD and CHC, considering mild fibrosis (FL: F0, F1, F2) and severe fibrosis (FA: F3, F4). As controls, subjects without alcohol consumption (CT) were recruited. Multiplex®-MERCK© was used for MMP-2 and -9 quantification. Statistical analysis was performed by Mann Whitney-U test, p<0.05, with SPSS V.22.

Results

The groups included were: 27 NAFLD (mild fibrosis: F0, F1, F2), 36 NAFLD (severe fibrosis: F3, F4), 48 CHC (mild fibrosis: F0, F1, F2), 54 CHC (severe fibrosis: F3, F4), 45 (CiOH), 99 (OH), and 138 CT. Both gelatinases, MMP-2 y MMP-9, were found elevated in CHC (mild and severe fibrosis) vs. CT; and decreased in OH, CiOH, HGNA (mild and severe fibrosis) vs. CT, plus there are significant differences between all etiologies, p<0.001.

Discussion

In patients with CHC, MMP-2 y -9 serum concentration increases, particularly in severe fibrosis stages, although it has no effect on ECM (extracellular matrix) degradation, as they are inactive. Nevertheless, there is a significant decrease in these gelatinases in ALD and NAFLD.

Conclusions

MMP-2 y MMP-9 module depends on the etiological agent involved, which can be useful for the differential diagnosis of liver diseases.

Funding

This work was partially financed by CONACyT SALUD-2016-272579 (GRG) and PAPIIT- UNAM TA200515 (GRG).

Declaration of interest

The authors declare no potential conflicts of interest.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos